Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study-Reference-Cited by-同舟云学术

Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study

Published:2022-04 Issue:4 Volume:9 Page:271-279
ISSN:2215-0366
Container-title:The Lancet Psychiatry
language:en
Short-container-title:The Lancet Psychiatry

Author:

Taipale Heidi,Tanskanen Antti,Correll Christoph U,Tiihonen Jari

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference28 articles.

1. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis;Leucht;Lancet,2012

2. Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms;Shimomura;Schizophr Res,2020

3. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode;Keating;BMJ Open,2017

4. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial;Wunderink;JAMA Psychiatry,2013

5. Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more;McGorry;JAMA Psychiatry,2013

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early intervention in psychosis in low- and middle-income countries: Applying the same principles as the developed countries;Asian Journal of Psychiatry;2024-09

2. Does relapse cause illness progression in first-episode psychosis? A review;Schizophrenia Research;2024-09

3. All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis;Molecular Psychiatry;2024-08-22

4. A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial;CNS Drugs;2024-07-02

5. Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia;JAMA Psychiatry;2024-06-26